ABXL
ABXLNYSENONENONE
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
—
Beta
—
52W High
$26.19
52W Low
$19.07
50-Day MA
$25.68
200-Day MA
$25.44
Dividend Yield
9.47%
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About ABXL
ABXL (Abraxas BioScience) is a biopharmaceutical company dedicated to advancing innovative therapies for serious medical conditions, focusing on areas with substantial unmet medical needs. The company's robust pipeline features proprietary drug candidates developed using cutting-edge technologies in drug discovery and development. Committed to scientific excellence and regulatory adherence, ABXL fosters collaboration with academic and industry stakeholders, enhancing its capability to deliver transformative treatments that aim to significantly improve patient outcomes in the healthcare landscape.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | 0.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | — |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | 0 |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
3.47%
HV 20-Day
5.00%
HV 30-Day
6.36%
HV 60-Day
7.06%
HV Rank
44.4%
Volatility is currently contracting
More NONE Stocks
SOJESouthern Company (The) Series 2DTGDTE Energy Company 2021 Series EDTBDTE Energy Company 2020 SeriesCGABLThe Carlyle Group Inc. 4.625% Subordinated Notes due 2061MGRBAffiliated Managers Group, Inc.NIQNIQ Global Intelligence plcUZDUnited States Cellular CorporatUZFUnited States Cellular CorporatRILYTB. Riley Financial Inc. 6.00% Senior Notes Due 2028HWCPZHancock Whitney Corporation - 6OXLCLOxford Lane Capital Corp. 6.75% Notes due 2031CCXIChurchill Capital Corp XI
Data last updated: 5/5/2026